CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Rucaparib and Nivolumabcombination
Likely dose
Rucaparib and Nivolumab 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03958045
NCT03958045Phase 2Completed
CompareCT.gov

Phase II Study of Combination Rucaparib With Nivolumab in Platinum-Sensitive Small Cell Lung Carcinoma Patients as Maintenance After Induction Therapy With Platinum Doublet

Zhonglin Hao·interventional·Posted May 21, 2019·Updated Oct 22, 2024

In Brief

A Phase 2 clinical trial evaluating Rucaparib and Nivolumab for Small Cell Lung Cancer. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate survival and response rate of the combination rucaparib and nivolumab as maintenance therapy in platinum-sensitive small cell lung carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesUnited States
CollaboratorsClovis Oncology, Inc.

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 21, 2019
Enrollment StartSep 4, 2019
Primary CompletionNov 15, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.1 years ago

Interventions

Rucaparib and Nivolumabcombination

Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)